It will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths
Alembic Pharmaceuticals Inc, the US subsidiary of Alembic Pharmaceuticals, has acquired Utility Therapeutics in a $12 million deal to strengthen its presence in the US market. Alembic will begin the commercialisation of Utility’s recently FDA-approved product Pivya (pivmethecillam) for the treatment of uncomplicated urinary tract infections. Pivya was approved by the FDA in April 2024.
Pranav Amin, MD, Alembic Pharmaceuticals, said, “This acquisition gives us a strategic entry into the specialty and branded prescription products. This will give us exposure to the branded pharmaceutical market with a near-term commercial launch.”
The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical products to the US Healthcare market. It will further enhance Alembic’s ability to build long-term value by combining global research, regulatory, and manufacturing strengths with a sharpened focus on speciality segments.
“We are thrilled that Alembic Pharmaceuticals understands the clinical and commercial value of PIVYA and will bring this proven treatment to female patients in need across the US,” said Tom Hadley, President and CEO, UTILITY Therapeutics. “With current therapies failing and the armament of uUTI antibiotics perilously thin, PIVYA provides US clinicians with a new and effective treatment option that has a long safety record.”
Craig Salmon, President, Alembic Pharmaceuticals, said “Since 2015, Alembic Pharmaceuticals US has grown its generics business to over 160 molecules and 413 products including generic dermaceutical, ophthalmic, general injectable, and oncology products. Entering the branded product market is the next phase of our US growth. Pivya represents an important and much-needed treatment option for patients with uncomplicated urinary tract infections. The acquisition of Utility broadens Alembic’s footprint beyond generic pharmaceuticals and will allow Alembic to build out its capabilities in the large US-branded pharmaceutical market. We plan to have PIVYA available in the US in Q4, 2025.”
